AIMOVIG (erenumab-aooe)
Aimovig (erenumab-aooe) is a calcitonin gene-related peptide (CGRP) receptor antagonist. It is indicated for the preventive treatment of migraine in adult patients. This medication serves as a prophylactic therapeutic option intended to manage the condition in adults who experience migraine.
How AIMOVIG Works
Erenumab-aooe is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. The drug binds to this specific receptor to antagonize its function. By blocking the CGRP receptor, the medication inhibits the biological activity and signaling pathways associated with the CGRP protein.
Details
- Status
- Prescription
- First Approved
- 2018-05-17
- Revenue
- $78M (Q4-2023)
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
AIMOVIG Approval History
What AIMOVIG Treats
1 indicationsAIMOVIG is approved for 1 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Migraine
AIMOVIG Target & Pathway
ProTarget
A neuropeptide involved in pain transmission and blood vessel dilation. CGRP levels rise during migraine attacks and contribute to headache pain. Blocking CGRP or its receptor prevents and treats migraines.
AIMOVIG Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to AIMOVIG
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
2 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05684692 | 22-512 | Ph 2 | recruiting | Screening Trial for Pain Relief in Schwannomatosis (STARFISH) |
| NCT05142228 results posted | HP-00097072 | Ph 2 | terminated | Erenumab-aooe for the Management of Trigeminal Neuropathic Pain. |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
AIMOVIG FDA Label Details
Indications & Usage
FDA Label (PDF)AIMOVIG is indicated for the treatment of Migraine.
Pro Intelligence Preview
Deep insights for AIMOVIG
Revenue Insights
- • Q4-2023: $78M
- • Historical trend analysis
Patent Timeline
- • Patent expiration dates
- • Generic/biosimilar risk
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.